Iovance Biotherapeutics, Inc. (IOVA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

19/25

Growth 5 Margin 5 Expansion 4 Platform 2 Financial 3

latest quarter score

Earnings Reports

19
IOVA Q2 2026: Margin Soars to 56% as Ampagni Demand Drives Record Scale
August 06, 2026
16
IOVA Q1 2026: Ampagni Revenue Up 38% as TIL Platform Expands Clinical Reach
May 07, 2026
19
IOVA Q4 2025: MTAGV Drives 30% Revenue Growth as Pipeline Expansion Accelerates
February 25, 2026
12
IOVA Q3 2025: Gross Margin Climbs to 43% as Internal Manufacturing Shift Accelerates Path to Profitability
November 06, 2025
13
IOVA Q2 2025: 19% Workforce Cut Targets Margin Lift as TIL Therapy Adoption Climbs
August 08, 2025
13
IOVA Q1 2025: Gross Margin Slumps to 10% Amid Manufacturing Disruptions and Revised Guidance
July 05, 2025
Iovance Biotherapeutics (IOVA) Q4 2024: $164M Revenue Caps Launch Year with 3x Growth Targeted for 2025
February 27, 2025

Browse all companies